New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder

Pr. Semir Nouira111 enrolled

Overview

the objective of this study is to : -Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker of HF in patients with CKD-MBD.

The disorders of mineral metabolism and bone disease are common complications in CKD patients and they are associated with increased morbidity and mortality. Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho. The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate early in in the advancement of CKD stage to attain levels in CKD stage 5D. But we still have few knoweledges if these markers can have some drawbacks for predicting CVD in early stage CKD.

Study Type

OBSERVATIONAL

Enrollment

111

Conditions

Kidney Disease, Chronic Heart Failure

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Early CKD stage * Heart failure Exclusion Criteria: * Infections * cancer * corticoid therapy * renal replacement therapy * Advanced CKD stage

Outcomes

Primary Outcomes

Fibroblast Growth Factor 23 (FGF23)

compare the circulating levels of FGF23 (pg/ml) in the two groups .

Time frame: completed data base (after 4 months)

Alpha Klotho

compare the circulating levels of klotho (ng/ml) in the two groups .

Time frame: completed data base (after 4 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.